Summit Therapeutics PLC (LON:SUMM) has been reiterated to Corporate in a report by N+1 Singer earlier today.
- Updated: September 27, 2016
Yesterday Summit Therapeutics PLC (LON:SUMM) traded -11.66% lower at 138.50GBX. SUMM’s 50-day average is 100.75GBX and its two hundred day average is 105.23GBX. With the last close up 25.93% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 91,871 shares of SUMM traded hands, up from an average trading volume of 44,113
N+1 Singer has reiterated Summit Therapeutics PLC (LON:SUMM) to Corporate in a report released on 09/28/2016.
Recent Performance Chart
Summit Therapeutics PLC has with a one year low of 82.66GBX and a one year high of 159.00GBX and has a market capitalization of 0 GBX.
General Information About Summit Therapeutics PLC (LON:SUMM)
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.